semaglutide 1.75 mg 1.75mg providing better and longer FDA approves obesity drug that

Structure Therapeutics reported Phase 2 data in March 2026 from its aleniglipron programme showing weight loss of up to 16.3% at 44 weeks, the highest efficacy yet reported for an oral small-molecule GLP-1 receptor agonist at that time point

its relevance to humans is unknown

Provides between 200 and 250 kcal Less than 30% of calories from fat High amount of good quality protein 30% of vitamins and minerals Understanding GLP-1 Injections and Meal Replacements GLP-1 injections are medications that mimic the glucagon-like peptide-1 hormone, which helps regulate blood sugar levels, slows digestion, and reduces appetite

doi: 10.1038/ncomms8489 17 ChangY.YangY.XuN.MuH.ZhangH.DuanJ

The following pre-processing was applied: motion correction using MCFLIRT 46 , B0 unwarping, slice-timing correction using Fourier-space time-series phase-shifting, non-brain removal using BET 52 , spatial smoothing using a Gaussian kernel of FWHM 8 mm, grand-mean intensity normalization of the entire 4D dataset by a single multiplicative factor, highpass temporal filtering (Gaussian-weighted least-squares straight line fitting, with sigma = 25.0 s)